Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty

Authors :: Serruys, P.W.J.C. (Patrick)
Klein, W.W. (Werner)
Tijssen, J.G.P. (Jan)
Rutsch, W.R. (Wolfgang)
Heyndrickx, G.R. (Guy)
Emanuelsson, H.U. (Hakan)
Ball, S.G. (Sarah)
Decoster, O.
Schoeder, E.
Liberman, H.
Eichhorn, E. (Edwin)
Willerson, J.T. (James)
Anderson, H.V. (Vernon)
Khaja, F.
Alexander, R.W. (Robert)
Baim, D.S. (Donald)
Melkert, R. (Rein)
Oene, J.C. van
Gool, R. van
Serruys, P.W.J.C. (Patrick)
Klein, W.W. (Werner)
Tijssen, J.G.P. (Jan)
Rutsch, W.R. (Wolfgang)
Heyndrickx, G.R. (Guy)
Emanuelsson, H.U. (Hakan)
Ball, S.G. (Sarah)
Decoster, O.
Schoeder, E.
Liberman, H.
Eichhorn, E. (Edwin)
Willerson, J.T. (James)
Anderson, H.V. (Vernon)
Khaja, F.
Alexander, R.W. (Robert)
Baim, D.S. (Donald)
Melkert, R. (Rein)
Oene, J.C. van
Gool, R. van
Publication Year :: 1993
Abstract: BACKGROUND. Ketanserin is a serotonin S2-receptor antagonist that inhibits the platelet activation and vasoconstriction induced by serotonin and also inhibits the mitogenic effect of serotonin on vascular smooth muscle cells. METHODS AND RESULTS. We conducted a randomized, double blind

Database :: OAIster
Notes :: application/pdf, Circulation (Baltimore) vol. 88 no. 4, pp. 1588-1601, English
Publication Type :: Electronic Resource
Accession number :: edsoai.ocn929978005
Document Type :: Electronic Resource

Tools